- call +1-201-465-4211
- email sales@mrinsights.biz
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
Scope of the Report:
The classification of Chemotherapy Induced Peripheral Neuropathy Treatment includes Calcium channel α2-delta ligands, Antidepressants, Opioids and Other Drugs. And the proportion of Opioids in 2017 is about 27%, and the proportion is in decreasing trend from 2013 to 2017.
Chemotherapy Induced Peripheral Neuropathy Treatment is widely used for CIPN cause by Platinum Agents, Taxanes, Vinca Alkaloids and Others. The most proportion of Chemotherapy Induced Peripheral Neuropathy Treatment is used in Platinum Agents, and the proportion in 2017 is 42%.
North America is the largest sales place, with a sales market share nearly 41% in 2017. Following North America, Europe is the second largest sales place with the sales market share of 27%.
The worldwide market for Chemotherapy Induced Peripheral Neuropathy Treatment is expected to grow at a CAGR of roughly 6.4% over the next five years, will reach 1880 million US$ in 2024, from 1300 million US$ in 2019, according to a new study.
This report focuses on the Chemotherapy Induced Peripheral Neuropathy Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Aptinyx
Asahi Kasei Pharma
Regenacy Pharmaceuticals
MAKScientific
Metys Pharmaceuticals
Nemus Bioscience
PledPharma
Sova Pharmaceuticals
DermaXon
Immune Pharmaceuticals
Kineta
Krenitsky Pharmaceuticals
PeriphaGen
Apexian Pharma
WinSanTor
Solasia Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Market Segment by Applications, can be divided into
Platinum Agents
Taxanes
Vinca Alkaloids
Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Chemotherapy Induced Peripheral Neuropathy Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, with price, sales, revenue and global market share of Chemotherapy Induced Peripheral Neuropathy Treatment in 2017 and 2018.
Chapter 3, the Chemotherapy Induced Peripheral Neuropathy Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Chemotherapy Induced Peripheral Neuropathy Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Chemotherapy Induced Peripheral Neuropathy Treatment market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Chemotherapy Induced Peripheral Neuropathy Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Calcium Channel α2-delta Ligands
1.2.2 Antidepressants
1.2.3 Opioids
1.2.4 Others
1.3 Market Analysis by Applications
1.3.1 Platinum Agents
1.3.2 Taxanes
1.3.3 Vinca Alkaloids
1.3.4 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Aptinyx
2.1.1 Business Overview
2.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Aptinyx Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Asahi Kasei Pharma
2.2.1 Business Overview
2.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Asahi Kasei Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Regenacy Pharmaceuticals
2.3.1 Business Overview
2.3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 MAKScientific
2.4.1 Business Overview
2.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 MAKScientific Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Metys Pharmaceuticals
2.5.1 Business Overview
2.5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Metys Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.6 Nemus Bioscience
2.6.1 Business Overview
2.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Nemus Bioscience Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.7 PledPharma
2.7.1 Business Overview
2.7.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.8 Sova Pharmaceuticals
2.8.1 Business Overview
2.8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Sova Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.9 DermaXon
2.9.1 Business Overview
2.9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 DermaXon Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.10 Immune Pharmaceuticals
2.10.1 Business Overview
2.10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Immune Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.11 Kineta
2.11.1 Business Overview
2.11.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Kineta Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.12 Krenitsky Pharmaceuticals
2.12.1 Business Overview
2.12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Krenitsky Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.13 PeriphaGen
2.13.1 Business Overview
2.13.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.14 Apexian Pharma
2.14.1 Business Overview
2.14.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.15 WinSanTor
2.15.1 Business Overview
2.15.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.16 Solasia Pharma
2.16.1 Business Overview
2.16.2 Chemotherapy Induced Peripheral Neuropathy Treatment Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Solasia Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Manufacturer (2017-2018)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturer Market Share in 2018
3.3.2 Top 6 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Regions
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Regions
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Regions (2014-2019)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Regions (2014-2019)
4.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
4.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
4.5 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
5 North America Chemotherapy Induced Peripheral Neuropathy Treatment by Country
5.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Country
5.1.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Country (2014-2019)
5.1.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Country (2014-2019)
5.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
5.3 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
5.4 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
6 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Country
6.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Country
6.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Country (2014-2019)
6.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Country (2014-2019)
6.2 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
6.3 UK Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
6.4 France Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
6.5 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
6.6 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
7 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment by Country
7.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Country (2014-2019)
7.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
7.3 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
7.4 Korea Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
7.5 India Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
7.6 Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
8 South America Chemotherapy Induced Peripheral Neuropathy Treatment by Country
8.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Country
8.1.1 South America Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Country (2014-2019)
8.1.2 South America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Country (2014-2019)
8.2 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
8.3 Argentina Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
8.4 Colombia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
9 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
9.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
9.3 Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
9.4 Egypt Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
9.5 Nigeria Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
9.6 South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Growth Rate (2014-2019)
10 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment by Type
10.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Market Share by Type (2014-2019)
10.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2014-2019)
10.2 Calcium Channel α2-delta Ligands Sales Growth and Price
10.2.1 Global Calcium Channel α2-delta Ligands Sales Growth (2014-2019)
10.2.2 Global Calcium Channel α2-delta Ligands Price (2014-2019)
10.3 Antidepressants Sales Growth and Price
10.3.1 Global Antidepressants Sales Growth (2014-2019)
10.3.2 Global Antidepressants Price (2014-2019)
10.4 Opioids Sales Growth and Price
10.4.1 Global Opioids Sales Growth (2014-2019)
10.4.2 Global Opioids Price (2014-2019)
10.5 Others Sales Growth and Price
10.5.1 Global Others Sales Growth (2014-2019)
10.5.2 Global Others Price (2014-2019)
11 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment by Application
11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2014-2019)
11.2 Platinum Agents Sales Growth (2014-2019)
11.3 Taxanes Sales Growth (2014-2019)
11.4 Vinca Alkaloids Sales Growth (2014-2019)
11.5 Others Sales Growth (2014-2019)
12 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast (2019-2024)
12.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Growth Rate (2019-2024)
12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Regions (2019-2024)
12.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast (2019-2024)
12.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast (2019-2024)
12.2.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast (2019-2024)
12.2.4 South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast (2019-2024)
12.2.5 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast (2019-2024)
12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Type (2019-2024)
12.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Type (2019-2024)
12.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Type (2019-2024)
12.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast by Application (2019-2024)
12.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Application (2019-2024)
12.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Chemotherapy Induced Peripheral Neuropathy Treatment Picture
Table Product Specifications of Chemotherapy Induced Peripheral Neuropathy Treatment
Figure Global Sales
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
